Neuberger Berman Group
TAK icon

Neuberger Berman Group’s Takeda Pharmaceutical TAK Stock Holding History

Neuberger Berman Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Sell
86,071
-8,953
-9% -$148K ﹤0.01% 1413
2026
Q1 		$1.76M Buy
95,024
+32,296
+51% +$567K ﹤0.01% 1224
2025
Q4 		$978K Buy
62,728
+14,274
+29% +$204K ﹤0.01% 1401
2025
Q3 		$709K Buy
48,454
+14,212
+42% +$211K ﹤0.01% 1474
2025
Q2 		$529K Buy
34,242
+3,533
+12% +$52.2K ﹤0.01% 1553
2025
Q1 		$457K Buy
30,709
+5,034
+20% +$70.5K ﹤0.01% 1549
2024
Q4 		$340K Buy
25,675
+9,081
+55% +$125K ﹤0.01% 1641
2024
Q3 		$236K Buy
16,594
+6,100
+58% +$86.5K ﹤0.01% 1747
2024
Q2 		$136K Sell
10,494
-5,533
-35% -$73.2K ﹤0.01% 1793
2024
Q1 		$223K Buy
+16,027
New +$233K ﹤0.01% 1720
2020
Q2 		– Sell
-10,808
Closed -$164K – 1602
2020
Q1 		$164K Buy
+10,808
New +$196K ﹤0.01% 1442

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Neuberger Berman Group's TAK Position: Q2 2026 in Review

Neuberger Berman Group reduced its Takeda Pharmaceutical (TAK) stake by 9.4% in Q2 2026, selling an estimated $148K and leaving 86,071 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1413.

Neuberger Berman Group first reported a position in TAK in Q1 2020 and has held it in 11 quarters since. The position peaked at $1.76M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Neuberger Berman Group held 86,071 shares of Takeda Pharmaceutical worth $1.38M as of Q2 2026.
  • Neuberger Berman Group sold 8,953 Takeda Pharmaceutical shares in Q2 2026, an estimated $148K.
  • Takeda Pharmaceutical made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1413 holding.
  • Neuberger Berman Group first reported a position in Takeda Pharmaceutical in Q1 2020 and has held it in 11 quarters since.
  • Neuberger Berman Group's Takeda Pharmaceutical position peaked at $1.76M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.